| Jul 29 |
ImmunoPrecise reports Q4 results
|
| Jul 29 |
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
|
| Jul 17 |
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
|
| Jul 15 |
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
|
| Jun 27 |
ImmunoPrecise appoints Kristin Taylor as CFO
|
| Jun 27 |
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
|
| Jun 25 |
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
|
| Jun 4 |
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
|
